Aclaris Therapeutics Inc. (NASDAQ:ACRS) major shareholder Ra Capital Management, Llc sold 525,550 shares of the company’s stock in a transaction that occurred on Friday, September 16th. The shares were sold at an average price of $24.19, for a total value of $12,713,054.50. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Shares of Aclaris Therapeutics Inc. (NASDAQ:ACRS) opened at 25.03 on Friday. The firm’s market capitalization is $536.02 million. Aclaris Therapeutics Inc. has a 12 month low of $10.99 and a 12 month high of $33.88. The stock’s 50 day moving average price is $21.38 and its 200-day moving average price is $19.76.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Thursday, August 11th. The company reported ($0.62) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by $0.01. On average, equities analysts anticipate that Aclaris Therapeutics Inc. will post ($2.61) earnings per share for the current fiscal year.
Several analysts have issued reports on ACRS shares. Zacks Investment Research cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 12th. Guggenheim started coverage on Aclaris Therapeutics in a research note on Friday, June 10th. They set a “buy” rating and a $35.00 price objective on the stock. Finally, Jefferies Group upped their price objective on Aclaris Therapeutics from $20.00 to $23.00 and gave the company a “buy” rating in a research note on Friday, August 12th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $31.25.
Several large investors have recently modified their holdings of ACRS. Nationwide Fund Advisors increased its stake in shares of Aclaris Therapeutics by 47.0% in the second quarter. Nationwide Fund Advisors now owns 5,747 shares of the company’s stock valued at $106,000 after buying an additional 1,838 shares in the last quarter. Tocqueville Asset Management L.P. acquired a new stake in shares of Aclaris Therapeutics during the second quarter valued at about $185,000. Teachers Advisors Inc. increased its stake in shares of Aclaris Therapeutics by 91.0% in the second quarter. Teachers Advisors Inc. now owns 14,212 shares of the company’s stock valued at $262,000 after buying an additional 6,772 shares in the last quarter. Swiss National Bank acquired a new stake in shares of Aclaris Therapeutics during the second quarter valued at about $283,000. Finally, Sabby Management LLC acquired a new stake in shares of Aclaris Therapeutics during the second quarter valued at about $292,000. 71.39% of the stock is currently owned by institutional investors.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.
Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.